Vukovic R, Kumburovic I, Joksimovic Jovic J, Jovicic N, Katanic Stankovic JS, Mihailovic V, et al
10.31662/jmaj.2020-0005 JMA J
doi: 10.1016/j.phrs.2024.107452 227 ZhouPMaYYZhaoXNHuaF
Protocol 1: moderate weight loss (10-15% body weight) Goal: Steady, sustainable weight loss with minimal side effects Tirzepatide approach: Standard escalation to 5-7.5 mg Hold at the dose where you achieve consistent weekly loss of 0.5-1% body weight Expected timeline: 24-36 weeks to target Likely maintenance dose: 5-7.5 mg Retatrutide approach: Standard escalation to 4 mg 4 mg delivered 12.9% weight loss at 24 weeks in trials Hold at 4 mg if achieving target rate Expected timeline: 20-30 weeks to target For moderate goals, both compounds work well at their lower dose ranges
PGs Targets In some reports, the key function of PGs is shown in physiological immune responses and pathological conditions related to inflammation and tissue damage
Acknowledgment The authors thank the College of Veterinary Medicine, University of Baghdad, for their support in this study
